Ixekizumab is a humanized monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in the pathogenesis of psoriasis and other inflammatory conditions [1]. It is used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Ixekizumab was developed by Eli Lilly and Company and has been approved by regulatory authorities worldwide, including the US FDA [2]. The drug's patent protection is set to expire in 2032, according to data from DrugPatentWatch.com [3].

Clinical trials have demonstrated that ixekizumab is effective in reducing symptoms of psoriasis, including plaque thickness and severity [4]. The drug has also been shown to improve quality of life for patients with psoriasis, reducing symptoms such as itching and pain [5].

Ixekizumab is administered via subcutaneous injection and is available in various formulations, including a prefilled syringe and a pen injector [6]. Common side effects of the drug include injection site reactions, upper respiratory tract infections, and headache [7].

Overall, ixekizumab is a valuable treatment option for patients with moderate to severe psoriasis and other inflammatory conditions.

Sources:

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444449/
[2] https://www.fda.gov/drugs/information-drug-class/drug-class-psoriasis
[3] https://www.drugpatentwatch.com/drug/ixekizumab
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444449/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444449/
[6] https://www.lilly.com/en-us/products/ixekizumab
[7] https://www.lilly.com/en-us/products/ixekizumab